Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma

Tohoku Journal of Experimental Medicine

Volumn 218, Issue 2, 2009, Pages 129-139

  Cho, Hanbyoul ^a   Lim, Beom Jin ^b   Kang, Eun Suk ^c   Choi, Joong Sub ^d   Kim, Jae Hoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Chungnam National University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Biomaker; Cell line; Characterization; Microarray; Ovarian cancer

Indexed keywords

BLEOMYCIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; ONCOPROTEIN; OXALIPLATIN; PACLITAXEL; PROTEIN CDCA7; PROTEIN LAMP3; PROTEIN P53; PROTEIN RGC32; PROTEIN SFN; PROTEIN SLCO4A1; TOPOTECAN; UNCLASSIFIED DRUG; ORGANIC COMPOUND; SYBR GREEN I;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN YDOV 151; CELL STRUCTURE; CONTROLLED STUDY; CYSTADENOCARCINOMA; DNA MICROARRAY; DRUG SENSITIVITY; ELECTRON MICROSCOPY; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROARRAY ANALYSIS; MICROSCOPY; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; XENOGRAFT; ADULT; ANIMAL; CANCER TRANSPLANTATION; CASE REPORT; CULTURE TECHNIQUE; DNA SEQUENCE; FATALITY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KINETICS; METHODOLOGY; MOLECULAR GENETICS; MOUSE; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; ANIMALS; BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTADENOCARCINOMA, MUCINOUS; FATAL OUTCOME; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; ORGANIC CHEMICALS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 68549087346     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.218.129     Document Type: Article

References (33)

1. Alama, A., Barbieri, F., Favre, A., Cagnoli, M., Noviello, E., Pedulla, F., Viale, M., Foglia, G. & Ragni, N. (1996) Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Gynecol. Oncol., 62, 82-88.
2. Baker, P.M. & Oliva, E. (2005) Immunohistochemistry as a tool in the differential diagnosis of ovarian tumors: an update. Int. J. Gynecol. Pathol., 24, 39-55.
3. Cannistra, S.A. (2004) Cancer of the ovary. N. Engl. J. Med., 351, 2519-2529.
4. Cooper, A. & DePriest, P. (2007) Surgical management of women with ovarian cancer. Semin. Oncol., 34, 226-233.
5. Durocher, F., Shattuck-Eidens, D., McClure, M., Labrie, F., Skolnick, M.H., Goldgar, D.E. & Simard, J. (1996) Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum. Mol. Genet., 5, 835-842.
6. Frank, T.S., Manley, S.A., Olopade, O.I., Cummings, S., Garber, J.E., Bernhardt, B., Antman, K., Russo, D., Wood, M.E., Mullineau, L., Isaacs, C., Peshkin, B., Buys, S., Venne, V., Rowley, P.T., Loader, S., Offit, K., Robson, M., Hampel, H., Brener, D., Winer, E.P., Clark, S., Weber, B., Strong, L.C., Thomas, A. & et al. (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol., 16, 2417-2425.
7. Friedman, L.S., Ostermeyer, E.A., Szabo, C.I., Dowd, P., Lynch, E.D., Rowell, S.E. & King, M.C. (1994) Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet., 8, 399-404.
8. Fujita, M., Enomoto, T. & Murata, Y. (2003) Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol. Cell. Endocrinol., 202, 97-99.
9. Greenblatt, M.S., Bennett, W.P., Hollstein, M. & Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
10. Gross, E., Arnold, N., Pfeifer, K., Bandick, K. & Kiechle, M. (2000) Identification of specific BRCA1 and BRCA2 variants by DHPLC. Hum. Mutat., 16, 345-353.
11. Hough, C.D., Sherman-Baust, C.A., Pizer, E.S., Montz, F.J., Im, D.D., Rosenshein, N.B., Cho, K.R., Riggins, G.J. & Morin, P.J. (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res., 60, 6281-6287.
12. Ishiwata, I., Ishiwata, C., Soma, M., Kobayashi, N. & Ishikawa, H. (1984) Establishment and characterization of an estrogen-producing human ovarian granulosa tumor cell line. J. Natl. Cancer Inst., 72, 789-800.
13. Jacobs, I.J., Kohler, M.F., Wiseman, R.W., Marks, J.R., Whitaker, R., Kerns, B.A., Humphrey, P., Berchuck, A., Ponder, B.A. & Bast, R.C., Jr. (1992) Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J. Natl. Cancer Inst., 84, 1793-1798.
14. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. & Thun, M.J. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
15. Kim, J.W., Lee, C.G., Lyu, M.S., Kim, H.K., Rha, J.G., Kim, D.H., Kim, S.J. & Namkoong, S.E. (1997) A new cell line from human undifferentiated carcinoma of the ovary: establishment and characterization. J. Cancer Res. Clin. Oncol., 123, 82-90.
16. Kim, Y.T., Nam, E.J., Yoon, B.S., Kim, S.W., Kim, S.H., Kim, J.H., Kim, H.K., Koo, J.S. & Kim, J.W. (2005) Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. Gynecol. Oncol., 99, 585-590.
17. Kohler, M.F., Marks, J.R., Wiseman, R.W., Jacobs, I.J., Davidoff, A.M., Clarke-Pearson, D.L., Soper, J.T., Bast, R.C., Jr. & Berchuck, A. (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst., 85, 1513-1519.
18. Kupryjanczyk, J., Thor, A.D., Beauchamp, R., Merritt, V., Edgerton, S.M., Bell, D.A. & Yandell, D.W. (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A., 90, 4961-4965.
19. Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
20. Majdak, E.J., De Bock, G.H., Brozek, I., Perkowska, M., Ochman, K., Debniak, J., Milczek, T., Cornelisse, C.J., Jassem, J., Emerich, J., Limon, J. & Devilee, P. (2005) Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur. J. Cancer, 41, 143-150.
21. McGuire, V., Jesser, C.A. & Whittemore, A.S. (2002) Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol. Oncol., 84, 399-403.
22. Miller, S.A., Dykes, D.D. & Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16, 1215.
23. Parham, P. (1996) Functions for MHC class I carbohydrates inside and outside the cell. Trends Biochem. Sci., 21, 427-433.
24. Raetz, E.A. & Moos, P.J. (2004) Impact of microarray technology in clinical oncology. Cancer Invest, 22, 312-320.
25. Reles, A., Wen, W.H., Schmider, A., Gee, C., Runnebaum, I.B., Kilian, U., Jones, L.A., El-Naggar, A., Minguillon, C., Schonborn, I., Reich, O., Kreienberg, R., Lichtenegger, W. & Press, M.F. (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res., 7, 2984-2997.
26. Risch, H.A., McLaughlin, J.R., Cole, D.E., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D.J., Kuperstein, G., Abrahamson, J.L., Fan, I., Wong, B. & Narod, S.A. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet., 68, 700-710.
27. Rosenberg, S.A. (2001) Progress in human tumour immunology and immunotherapy. Nature, 411, 380-384.
28. Sato, S., Kobayashi, Y., Okuma, Y., Kondo, H., Kanishi, Y., Saito, K. & Kiguchi, K. (2002) Establishment and characterization of a cell-line originated from human mucinous cystadenocarcinoma of the ovary. Hum. Cell, 15, 171-177.
29. Scully, R. & Livingston, D.M. (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature, 408, 429-432.
30. Song, K., Li, Z., Seth, P., Cowan, K.H. & Sinha, B.K. (1997) Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas. Oncol. Res., 9, 603-609.
31. van Niekerk, C.C., Poels, L.G., Jap, P.H., Smeets, D.F., Thomas, C.M., Ramaekers, F.C. & Vooijs, G.P. (1988) Characterization of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma. Int. J. Cancer, 42, 104-111.
32. Vikhanskaya, F., Clerico, L., Valenti, M., Stanzione, M.S., Broggini, M., Parodi, S. & Russo, P. (1997) Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53. Int. J. Cancer, 72, 155-159.
33. Wagner, T., Stoppa-Lyonnet, D., Fleischmann, E., Muhr, D., Pages, S., Sandberg, T., Caux, V., Moeslinger, R., Langbauer, G., Borg, A. & Oefner, P. (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics, 62, 369-376.